INNT
TOTAL INVALIDATION PROCESSED BY THE IB
09/29/2024
Back to search
Official data from USPTO
BRAINEVER
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
BRAINEVER
ST13
US500000079188386Class
5, 10, 42, 44
Filing
79188386
Registration
5220280
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
36
Latest update
09/29/2024
Trademark type
Word
Nice classes
5, 10, 42, 44
Filing date
02/12/2016
Registration date
06/13/2017
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
12/29/2023
Last transaction
12/29/2023
Responsible office
United States Patent and Trademark Office
Status code
709
Official register
Principal Register
Drawing code
4
Owner type
99
Owner location
PARIS, FR
Examiner
GUTTADAURO, JULIE MARIE
Law office
L60
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
BRAINEVER
Representatives
Jeannine A Rittenhouse IpHorgan Ltd.
Technical classification
Nice Classes
Class 5Class 10Class 42Class 44
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceutical products for the protectionthe treatment of brain and spinal cord diseases or degenerative disorders and for improving neurological abilitiespharmaceutical compositions for the treatment of brain and spinal cord diseases or degenerative disorders; pharmaceutical products for the treatment of all cognitive deficiencies and neurodegenerative diseases; sanitary products for medical purposesnamely for the treatment of all cognitive deficienciesneurodegenerative diseasesbrain and spinal cord diseases or degenerative disorders and for improving neurological abilities; chemo-pharmaceutical products for the treatment of all cognitive deficienciesneurodegenerative diseasesbrain and spinal cord diseases or degenerative disorders and for improving neurological abilities; biological preparations for medical usenamely for the treatment of all cognitive deficienciesneurodegenerative diseasesbrain and spinal cord diseases or degenerative disorders and for improving neurological abilities; chemical preparations for medical or pharmaceutical usenamely for the treatment of all cognitive deficienciesneurodegenerative diseasesbrain and spinal cord diseases or degenerative disorders and for improving neurological abilities; diagnostic products for medical usenamely for the treatment of all cognitive deficienciesneurodegenerative diseasesbrain and spinal cord diseases or degenerative disorders and for improving neurological abilities; medicines for human medicine for the treatment of all cognitive deficienciesneurodegenerative diseasesbrain and spinal cord diseases or degenerative disorders and for improving neurological abilities
Class 10
Surgicalmedical apparatus and instruments for the preventiontreatment and repair of neurodegenerative diseases; testing apparatus used for the treatment of all cognitive deficiencies and neurodegenerative diseases and for the treatment of brain and spinal cord diseases or degenerative disorders and for improving neurological abilities
Class 42
Research and development of pharmaceutical products; biotechnology research and development; scientific and technological services as well as research and design services relating to the development of treatments for neurodegenerative diseases; biological research in the field of the treatment of all cognitive deficiencies and neurodegenerative diseasesthe treatment of brain and spinal cord diseases or degenerative disordersbacteriological research in the field of the treatment of all cognitive deficiencies and neurodegenerative diseasesthe treatment of brain and spinal cord diseases or degenerative disorderschemical research in the field of the treatment of all cognitive deficiencies and neurodegenerative diseasesthe treatment of brain and spinal cord diseases or degenerative disorders; medical and parapharmaceutical research in the field of the treatment of all cognitive deficiencies and neurodegenerative diseasesthe treatment of brain and spinal cord diseases or degenerative disorders; laboratory services and scientific research services particularly in the field of genetics; medical research in the field of brain diseases; technical information services relating to medicalpharmaceuticalparapharmaceutical and surgical activities; genetic research services; planning and development (design) of technical projects in the field of genetics; research and development in the field of medicine and genetics; scientific research and development services for the protectiontreatment of brain and spinal cord diseases or degenerative disorders and for improving neurological abilities; design and development of procedures and techniques for the treatment of brain and spinal cord diseases and for improving neurological abilities; clinical trials of treatments for neurodegenerative diseasesbrain or spinal cord diseasescognitive deficiencies and degenerative disorders and of diagnostic methods in the field of these diseases and genetics
Class 44
Medical care services for neurodegenerative diseases; medical care for the treatment of brain diseases; surgical treatments of the brain and spinal cord; therapy services; diagnosing and evaluating individuals with Alzheimer's disease or any other cognitive deficiency
Publications
History of USPTO decisions and trademark events.
36 publications found
INTS
TOTAL INVALIDATION OF REG EXT PROTECTION SENT TO IB
09/06/2024
INPC
INVALIDATION PROCESSED
09/06/2024
INTR
TOTAL INVALIDATION OF REG EXT PROTECTION CREATED
08/30/2024
C71T
CANCELLED SECTION 71
12/29/2023
REM3
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
06/13/2022
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
10/28/2017
FICS
FINAL DISPOSITION NOTICE SENT TO IB
09/21/2017
FIMP
FINAL DISPOSITION PROCESSED
09/21/2017
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
09/13/2017
R.PR
REGISTERED-PRINCIPAL REGISTER
06/13/2017
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
03/28/2017
PUBO
PUBLISHED FOR OPPOSITION
03/28/2017
GPNX
NOTIFICATION PROCESSED BY IB
03/25/2017
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
03/08/2017
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
03/08/2017
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
03/08/2017
PREV
LAW OFFICE PUBLICATION REVIEW COMPLETED
02/21/2017
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
02/09/2017
DOCK
ASSIGNED TO EXAMINER
02/02/2017
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
01/31/2017
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
01/31/2017
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
01/31/2017
ALIE
ASSIGNED TO LIE
01/27/2017
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
01/10/2017
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
01/10/2017
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
01/10/2017
RFNT
REFUSAL PROCESSED BY IB
07/29/2016
MAFR
APPLICATION FILING RECEIPT MAILED
07/12/2016
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
07/11/2016
RFRR
REFUSAL PROCESSED BY MPU
07/11/2016
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
07/09/2016
CNRT
NON-FINAL ACTION WRITTEN
07/08/2016
DOCK
ASSIGNED TO EXAMINER
07/08/2016
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
07/08/2016
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
07/07/2016
Continuous trademark protection
Get notified about every new filing that threatens BRAINEVER or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.